LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg.

    Meschi, Silvia / Mizzoni, Klizia / Leoni, Bruno Daniele / Galli, Claudio / Garbuglia, Anna Rosa / Belladonna, Stefano / Girardi, Enrico / Maggi, Fabrizio / The Hbsagn Study Group

    Viruses

    2024  Volume 16, Issue 3

    Abstract: We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who ...

    Abstract We investigated the frequency and serological correlates of occult hepatitis B virus infection (OBI) and the potential impact of a highly sensitive assay for HBsAg in subjects infected by human immunodeficiency virus (HIV) or hepatitis C virus (HCV), who are also at risk for hepatitis B virus (HBV) infection, often in an occult form. Samples from 499 patients with HIV, all HBsAg negative and anti-HBc positive, and 137 patients with HCV were tested for HBV-DNA, anti-HBc, anti-HBs, and HBsAg by a conventional and highly sensitive assay. HBV biomarkers were detected in 71.5% of HCV-RNA-positive, with a higher prevalence of cases positive only for anti-HBc in patients with HCV than in those with HIV. HBV-DNA was detectable in 0.6% of HIV-positive and 7.3% of HCV-RNA-positive patients. Among patients with HCV, four were positive for HBsAg and negative for HBV-DNA, bringing the rate of HBV-active infection in this group to 10.2%. Active HBV infection was not related to gender or specific patterns of HBV biomarkers but was higher in HCV patients coinfected by HIV compared to those infected only by HCV. Monitoring patients at high risk for HBV infection and reactivation may require testing for both HBV-DNA and HBsAg.
    MeSH term(s) Humans ; Hepatitis B virus/genetics ; Hepacivirus/genetics ; Hepatitis B Surface Antigens ; DNA, Viral ; HIV/genetics ; HIV Infections ; Hepatitis B/diagnosis ; Hepatitis B/epidemiology ; Hepatitis C/diagnosis ; Hepatitis C/epidemiology ; Hepatitis B, Chronic ; Hepatitis B Antibodies ; Prevalence ; Biomarkers ; RNA
    Chemical Substances Hepatitis B Surface Antigens ; DNA, Viral ; Hepatitis B Antibodies ; Biomarkers ; RNA (63231-63-0)
    Language English
    Publishing date 2024-03-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v16030412
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel.

    Santoro, Annapaola / Capri, Andrea / Petrone, Daniele / Colavita, Francesca / Meschi, Silvia / Matusali, Giulia / Mizzoni, Klizia / Notari, Stefania / Agrati, Chiara / Goletti, Delia / Pezzotti, Patrizio / Puro, Vincenzo

    Biomedicines

    2023  Volume 11, Issue 5

    Abstract: Background: Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of ... ...

    Abstract Background: Vaccine-induced SARS-CoV-2-anti-spike antibody (anti-S/RBD) titers are often used as a marker of immune protection and to anticipate the risk of breakthrough infections, although no clear cut-off is available. We describe the incidence of SARS-CoV-2 vaccine breakthrough infections in COVID-19-free personnel of our hospital, according to B- and T-cell immune response elicited one month after mRNA third dose vaccination.
    Methods: The study included 487 individuals for whom data on anti-S/RBD were available. Neutralizing antibody titers (nAbsT) against the ancestral Whuan SARS-CoV-2, and the BA.1 Omicron variant, and SARS-CoV-2 T-cell specific response were measured in subsets of 197 (40.5%), 159 (32.6%), and 127 (26.1%) individuals, respectively.
    Results: On a total of 92,063 days of observation, 204 participants (42%) had SARS-CoV-2 infection. No significant differences in the probability of SARS-CoV-2 infection for different levels of anti-S/RBD, nAbsT, Omicron nAbsT, or SARS-CoV-2 T cell specific response, and no protective thresholds for infection were found.
    Conclusions: Routine testing for vaccine-induced humoral immune response to SARS-CoV-2 is not recommended if measured as parameters of 'protective immunity' from SARS-CoV-2 after vaccination. Whether these findings apply to new Omicron-specific bivalent vaccines is going to be evaluated.
    Language English
    Publishing date 2023-04-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines11051247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.

    Colavita, Francesca / Matusali, Giulia / Mazzotta, Valentina / Bettini, Aurora / Lapa, Daniele / Meschi, Silvia / Francalancia, Massimo / Pinnetti, Carmela / Bordi, Licia / Mizzoni, Klizia / Coen, Sabrina / Girardi, Enrico / Vaia, Francesco / Nicastri, Emanuele / Antinori, Andrea / Maggi, Fabrizio

    Journal of medical virology

    2023  Volume 95, Issue 6, Page(s) e28851

    Abstract: Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody ... ...

    Abstract Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody response in patients with acute MPXV infection during the 2022 multicountry outbreak. A total of 64 samples from 18 MPXV-positive patients were longitudinally collected from the day of symptom onset (DSO) up to 20 days after and tested for anti-MPXV immunoglobulin G (IgG), IgM, IgA, and neutralizing antibodies (nAb) using the whole-live virus isolated in May 2022. IgG, IgM, and IgA were detected as early as 4 DSO (median time of seroconversion 7.5 DSO for IgG, 8 DSO for IgM and IgA). Anti-MPXV nAb were detectable in samples collected as early as 1 week after symptoms, with stable levels up to 20 DSO. After 2 weeks, IgG and nAb reached high titers. No significant differences were observed regardless of status of smallpox vaccination, human immunodeficiency virus positivity, or disease severity. Significant lower levels of IgM and IgG were observed in the patients treated with antivirals. These results contribute to extending the knowledge of the MPXV infection and the antibody response in a population with no historic smallpox vaccination.
    MeSH term(s) Humans ; Monkeypox virus ; Immunoglobulin G ; Immunoglobulin M ; Smallpox ; Antibody Formation ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A ; Disease Outbreaks
    Chemical Substances Immunoglobulin G ; Immunoglobulin M ; Antibodies, Viral ; Antibodies, Neutralizing ; Immunoglobulin A
    Language English
    Publishing date 2023-06-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 752392-0
    ISSN 1096-9071 ; 0146-6615
    ISSN (online) 1096-9071
    ISSN 0146-6615
    DOI 10.1002/jmv.28851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1320: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers.

    Anticoli, Simona / Dorrucci, Maria / Iessi, Elisabetta / Chiarotti, Flavia / Di Prinzio, Reparata Rosa / Vinci, Maria Rosaria / Zaffina, Salvatore / Puro, Vincenzo / Colavita, Francesca / Mizzoni, Klizia / Meschi, Silvia / Vonesch, Nicoletta / Albano, Christian / Ortona, Elena / Ruggieri, Anna / Tomao, Paola

    Human vaccines & immunotherapeutics

    2023  Volume 19, Issue 3, Page(s) 2273697

    Abstract: Healthcare workers (HCWs) are the target population for vaccination against coronavirus disease (COVID-19) as they are at a high risk of exposure and transmission of pathogens to patients. Neutralizing antibodies developed after COVID-19 vaccination ... ...

    Abstract Healthcare workers (HCWs) are the target population for vaccination against coronavirus disease (COVID-19) as they are at a high risk of exposure and transmission of pathogens to patients. Neutralizing antibodies developed after COVID-19 vaccination decline within few months of vaccination. Several factors, including age and sex, can affect the intensity, efficacy, and duration of immune response to vaccines. However, sex-specific analyses of humoral responses to COVID-19 vaccines are lacking. This study aimed to evaluate sex-based differences in anti-S/RBD (Receptor Binding Domain) responses at three different time points after the second dose of mRNA COVID-19 vaccine in HCWs in relation to age, and to investigate the role of sex hormones as potential markers of response. Anti-S/RBD levels after two doses of the mRNA vaccine were collected from 521 HCWs naïve to COVID-19, working at two Italian Clinical Centers. Multiple regression analysis was applied to evaluate the association between anti-S levels and sex, age, and plasma levels of sex hormones. Significantly higher anti-S/RBD response to the COVID-19 vaccination was found in female HCWs, and a significant and more abrupt decline in response with time was observed in women than that in men. A novel, positive association of testosterone plasma levels and higher anti-S levels in male HCWs was found, suggesting its potential role as sex specific marker in males. In conclusion, understanding the sex-based differences in humoral immune responses to vaccines may potentially improve vaccination strategies and optimize surveillance programs for HCWs.
    MeSH term(s) Humans ; Female ; Male ; Antibody Formation ; COVID-19 Vaccines ; COVID-19/prevention & control ; Vaccination ; Gonadal Steroid Hormones ; Antibodies, Neutralizing ; Health Personnel ; Antibodies, Viral
    Chemical Substances COVID-19 Vaccines ; Gonadal Steroid Hormones ; Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2023-11-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2664176-8
    ISSN 2164-554X ; 2164-5515
    ISSN (online) 2164-554X
    ISSN 2164-5515
    DOI 10.1080/21645515.2023.2273697
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6967: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.

    D'Apice, Luciana / Trovato, Maria / Gramigna, Giulia / Colavita, Francesca / Francalancia, Massimo / Matusali, Giulia / Meschi, Silvia / Lapa, Daniele / Bettini, Aurora / Mizzoni, Klizia / Aurisicchio, Luigi / Di Caro, Antonino / Castilletti, Concetta / De Berardinis, Piergiuseppe

    Frontiers in immunology

    2022  Volume 13, Page(s) 981693

    Abstract: Objectives: Emergence of new variants of SARS-CoV-2 might affect vaccine efficacy. Therefore, assessing the capacity of sera to neutralize variants of concern (VOCs) in BSL-2 conditions will help evaluating the immune status of population following ... ...

    Abstract Objectives: Emergence of new variants of SARS-CoV-2 might affect vaccine efficacy. Therefore, assessing the capacity of sera to neutralize variants of concern (VOCs) in BSL-2 conditions will help evaluating the immune status of population following vaccination or infection.
    Methods: Pseudotyped viruses bearing SARS-CoV-2 spike protein from Wuhan-Hu-1/D614G strains (wild type, WT), B.1.617.2 (Delta), or B.1.1.529 (Omicron) VOCs were generated to assess the neutralizing antibodies (nAbs) activity by a pseudovirus-based neutralization assay (PVNA). PVNA performance was assessed in comparison to the micro-neutralization test (MNT) based on live viruses. Sera collected from COVID-19 convalescents and vaccinees receiving mRNA (BNT16b2 or mRNA-1273) or viral vector (AZD1222 or Ad26.COV2.S) vaccines were used to measure nAbs elicited by two-dose BNT16b2, mRNA-1273, AZD1222 or one-dose Ad26.CO2.S, at different times from completed vaccination, ~ 1.5 month and ~ 4-6 months. Sera from pre-pandemic and unvaccinated individuals were analyzed as controls. Neutralizing activity following booster vaccinations against VOCs was also determined.
    Results: PVNA titers correlated with the gold standard MNT assay, validating the reliability of PVNA. Sera analyzed late from the second dose showed a reduced neutralization activity compared to sera collected earlier. Ad26.CO2.S vaccination led to very low or absent nAbs. Neutralization of Delta and Omicron BA.1 VOCs showed significant reduction of nAbs respect to WT strain. Importantly, booster doses enhanced Omicron BA.1 nAbs, with persistent levels at 3 months from boosting.
    Conclusions: PVNA is a reliable tool for assessing anti-SARS-CoV-2 nAbs helping the establishment of a correlate of protection and the management of vaccination strategies.
    MeSH term(s) Ad26COVS1 ; Antibodies, Neutralizing ; COVID-19/prevention & control ; Carbon Dioxide ; ChAdOx1 nCoV-19 ; Humans ; Membrane Glycoproteins/metabolism ; RNA Viruses ; RNA, Messenger ; Reproducibility of Results ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins
    Chemical Substances Ad26COVS1 ; Antibodies, Neutralizing ; Membrane Glycoproteins ; RNA, Messenger ; Spike Glycoprotein, Coronavirus ; Viral Envelope Proteins ; spike protein, SARS-CoV-2 ; Carbon Dioxide (142M471B3J) ; ChAdOx1 nCoV-19 (B5S3K2V0G8)
    Language English
    Publishing date 2022-09-26
    Publishing country Switzerland
    Document type Comparative Study ; Journal Article
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.981693
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.

    Matusali, Giulia / Petruccioli, Elisa / Cimini, Eleonora / Colavita, Francesca / Bettini, Aurora / Tartaglia, Eleonora / Sbarra, Settimia / Meschi, Silvia / Lapa, Daniele / Francalancia, Massimo / Bordi, Licia / Mazzotta, Valentina / Coen, Sabrina / Mizzoni, Klizia / Beccacece, Alessia / Nicastri, Emanuele / Pierelli, Luca / Antinori, Andrea / Girardi, Enrico /
    Vaia, Francesco / Sette, Alessandro / Grifoni, Alba / Goletti, Delia / Puro, Vincenzo / Maggi, Fabrizio

    Vaccines

    2023  Volume 11, Issue 10

    Abstract: When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to evaluate whether residual immunity from smallpox vaccination provided cross-protection. To assess the cross-immune response to MPXV, we collected serum samples ( ...

    Abstract When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to evaluate whether residual immunity from smallpox vaccination provided cross-protection. To assess the cross-immune response to MPXV, we collected serum samples (
    Language English
    Publishing date 2023-09-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines11101541
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding.

    Lapa, Daniele / Carletti, Fabrizio / Mazzotta, Valentina / Matusali, Giulia / Pinnetti, Carmela / Meschi, Silvia / Gagliardini, Roberta / Colavita, Francesca / Mondi, Annalisa / Minosse, Claudia / Scorzolini, Laura / Cicalini, Stefania / Maffongelli, Gaetano / Specchiarello, Eliana / Camici, Marta / Bettini, Aurora / Baldini, Francesco / Francalancia, Massimo / Mizzoni, Klizia /
    Garbuglia, Anna Rosa / Nicastri, Emanuele / Girardi, Enrico / Antinori, Andrea / Vaia, Francesco / Maggi, Fabrizio

    The Lancet. Infectious diseases

    2022  Volume 22, Issue 9, Page(s) 1267–1269

    MeSH term(s) HIV-1 ; Humans ; Monkeypox virus ; RNA, Viral ; Semen ; Virus Shedding
    Chemical Substances RNA, Viral
    Language English
    Publishing date 2022-08-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(22)00513-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5743: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top